Insider Buying: GSK (LON:GSK) Insider Buys 637 Shares

GSK plc (LON:GSK – Get Free Report) insider Anne Beal purchased 637 shares of GSK stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45.

GSK Trading Down 0.3%

Shares of GSK stock traded down GBX 5 during trading hours on Tuesday, hitting GBX 1,906. The company had a trading volume of 5,121,120 shares, compared to its average volume of 13,080,331. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a market capitalization of £76.37 billion, a PE ratio of 16.18, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company’s fifty day moving average is GBX 1,889.93 and its 200 day moving average is GBX 1,951.92. GSK plc has a fifty-two week low of GBX 1,455 and a fifty-two week high of GBX 2,282.

Get GSK alerts:

GSK (LON:GSK – Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Research analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GSK shares. Berenberg Bank lifted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Tuesday, September 15th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

Check Out Our Latest Stock Report on GSK

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Stories

• Five stocks we like better than GSK
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA’s AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.